Isopropyl-dimethyl-methylene-λ⁵-phosphane | 29865-42-7

• 分子结构分类: 有机化合物 - 有机金属化合物
• 英文名称: Isopropyl-dimethyl-methylene-λ⁵-phosphane
• 英文别名: Dimethyl-methylidene-propan-2-yl-lambda5-phosphane；dimethyl-methylidene-propan-2-yl-λ5-phosphane
• CAS: 29865-42-7
• 化学式: C₆H₁₅P
• 分子量: 118.159
• InChiKey: QLOMXHQLTJPRAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  Trimethyl-isopropyl-phosphonium 在 正丁基锂 作用下， 以 乙醚 为溶剂， 生成 Isopropyl-dimethyl-methylene-λ⁵-phosphane
  参考文献：
  名称：

  Schmidbaur,H.; Malisch,W., Chemische Berichte, 1970, vol. 103, p. 3007 - 3018

  摘要：

  DOI：

文献信息

• BICYCLIC MORPHOLINO COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US20160186175A1

  公开（公告）日：2016-06-30

  The present invention provides bicyclic morpholino compounds and oligomeric compounds prepared therefrom. More particularly, incorporation of one or more of the bicyclic morpholino compounds into an oligomeric compound is expected to enhance one or more properties of the oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

  本发明提供双环吗啉化合物及其制备的寡聚化合物。更具体地，将一个或多个双环吗啉化合物并入寡聚化合物中，预计会增强寡聚化合物的一种或多种性质。此类寡聚化合物也可以包含在双链结构中。在某些实施例中，本发明提供的寡聚化合物预计会与目标RNA的一部分杂交，导致目标RNA的正常功能丧失。
• 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
  申请人：Prakash Thazha P.

  公开号：US20130116420A1

  公开（公告）日：2013-05-09

  The present invention provides 5′ modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5′-substituent and an optional 2′ substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

  本发明提供了由其制备的5′修饰核苷和寡聚合物化合物。更具体地，本发明提供了至少具有一个5′-取代基和一个可选的2′取代基的修饰核苷，包括至少其中一种修饰核苷的寡聚合物化合物以及使用这些寡聚合物化合物的方法。在某些实施例中，本文提供的寡聚合物化合物预计将与目标RNA的部分杂交，导致目标RNA的正常功能丧失。
• LIPID FORMULATED SINGLE STRANDED RNA
  申请人：Manoharan Muthiah

  公开号：US20130156845A1

  公开（公告）日：2013-06-20

  The present invention provides compositions comprising a nucleic acid lipid particle and an oligomeric compound and uses thereof. In certain embodiments, such compositions are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.

  本发明提供了包含核酸脂质粒子和寡核苷酸化合物的组合物及其用途。在某些实施方式中，这些组合物可用作反义物质。某些这样的反义物质可用作RNase H反义物质或RNAi物质。
• BASE MODIFIED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
  申请人：Allerson Charles

  公开号：US20130041011A1

  公开（公告）日：2013-02-14

  Provided herein are novel base modified bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel pyrimidine bicyclic nucleosides are provided wherein each pyrimidine base is substituted at the 5 position with an optionally substituted, aromatic or heteroaromatic ring system comprising from 5 to 7 ring atoms selected from C, N, O and S. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

  本文提供了新颖的碱基修饰的双环核苷酸、由此制备的寡聚合物化合物以及使用这些寡聚合物化合物的方法。更具体地，提供了新颖的嘧啶双环核苷酸，其中每个嘧啶碱基在5位被一个可选择取代的芳香或杂芳环系统取代，该环系统包括由C、N、O和S中选择的5至7个环原子。在某些实施方式中，本文提供的寡聚合物化合物与靶RNA的部分杂交，导致靶RNA的正常功能丧失。
• [EN] GOLD (I)-PHOSPHINE COMPOUNDS AS ANTI-BACTERIAL AGENTS<br/>[FR] COMPOSÉS À BASE D'OR (I)-PHOSPHINE EN TANT QU'AGENTS ANTI-BACTÉRIENS
  申请人：AUSPHERIX LTD

  公开号：WO2015181550A1

  公开（公告）日：2015-12-03

  A compound of formula (I) for use in the prevention or treatment of a bacterial infection wherein RP1 is either methyl, ethyl, isopropyl, cyclohexyl or phenyl; RP2 is selected from methyl, ethyl, isopropyl, cyclohexyl and phenyl; RP3 is either ethyl, isopropyl, cyclohexyl, phenyl or pyridyl; A is either S or Se; RA is selected from wherein each of Y1, Y2, Y3, Y4 and Y9 is independently selected from CH or N, wherein at least three of Y1, Y2, Y3, Y4 and Y9 are CH; V is selected from O, CH-ORO1, N-CO2-RC2 or N-RN2; one of Y5, Y6, Y7 and Y8 is selected from CH and N, and the others are CH; X is selected from NH, S or O; RC1 is selected from O-RO2 or NHRN1; RO1 is selected from H and C1-3 unbranched alkyl; RO2 is C1-3 unbranched alkyl; RN1 is selected from H and C1-3 unbranched alkyl; RN2 is C1-3 unbranched alkyl; RC2 is either C1-3 unbranched alkyl or C3-4 branched alkyl; RC3 is selected from C1-3 unbranched alkyl and C2H4CO2H; RC4 is either H or Me; RC5 is either H or Me; RC6 represents one or two optional methyl substituents; and n is an integer from 2 to 8.

  公式（I）的化合物用于预防或治疗细菌感染，其中RP1为甲基、乙基、异丙基、环己基或苯基之一；RP2从甲基、乙基、异丙基、环己基和苯基中选择；RP3为乙基、异丙基、环己基、苯基或吡啶基之一；A为S或Se；RA从Y1、Y2、Y3、Y4和Y9中选择，其中Y1、Y2、Y3、Y4和Y9中至少有三个是CH；V从O、CH-ORO1、N-CO2-RC2或N-RN2中选择；Y5、Y6、Y7和Y8中的一个从CH和N中选择，其余为CH；X从NH、S或O中选择；RC1从O-RO2或NHRN1中选择；RO1从H和C1-3直链烷基中选择；RO2为C1-3直链烷基；RN1从H和C1-3直链烷基中选择；RN2为C1-3直链烷基；RC2为C1-3直链烷基或C3-4支链烷基之一；RC3从C1-3直链烷基和C2H4 H中选择；RC4为H或Me；RC5为H或Me；RC6代表一个或两个可选的甲基取代基；n为2到8之间的整数。